ROS-Responsive Nanoparticles for Suppressing the Cytotoxicity and Immunogenicity Caused by PM2.5 Particulates.
ROS-Responsive Nanoparticles for Suppressing the Cytotoxicity and Immunogenicity Caused by PM2.5 Particulates.
复制标题
DOI：
10.1021/acs.biomac.9b00174
复制
发表时间：
2019-03
影响因子：
6.2
通讯作者：
Yixian Zhang;Haolan Zhang;Z. Mao;Changyou Gao
中科院分区：
文献类型：
--
作者：
Yixian Zhang;Haolan Zhang;Z. Mao;Changyou Gao
虽然颗粒物（PM2.5）对人类健康的负面影响已得到充分认识，但很少有人努力寻找新的策略来抑制PM2.5的体外和体内毒性。在这项研究中，活性氧（ROS）响应纳米粒子制成的聚（1，4-苯丙酮二亚甲基缩硫酮）（PPADT）用于负载免疫抑制剂药物他克莫司（FK 506）的药物负载效率约为44%。PPADT颗粒表现出非常好的ROS响应性，并在氧化环境中降解。通过清除细胞内活性氧，它们可以有效地抑制来自中国三个不同地区的PM2.5颗粒物对A549肺上皮细胞和RAW264.7巨噬细胞的毒性。此外，PM2.5的炎症反应也可被显著抑制，在体外和体内均显示出比游离FK 506药物更好的性能。这项概念验证性研究表明，ROS敏感药物释放颗粒在消除PM2.5污染物的毒性和抑制炎症方面具有广阔的应用前景，为生物纳米技术和医疗保健领域的刺激响应系统的设计和应用提供了新的思路。
Although the negative impacts of particulate matter (PM2.5) on human health have been well recognized, very few efforts have been paid to find new strategies to suppress the toxicity of PM2.5 both in vitro and in vivo. In this study, reactive oxygen species (ROS)-responsive nanoparticles made of poly(1,4-phenleneacetonedimethylene thioketal) (PPADT) were used to load immunosuppressant drug tacrolimus (FK506) with a drug loading efficiency of around 44%. The PPADT particles showed very good ROS-responsiveness and were degraded in an oxidation environment. By exhausting intracellular ROS, they could effectively suppress the toxicity of A549 lung epithelial cells and RAW264.7 macrophages induced by the PM2.5 particulates collected from three different regions in China. Moreover, the inflammatory response of PM2.5 could also be significantly suppressed, showing much better performance than the free FK506 drugs both in vitro and in vivo. This concept-proving research demonstrates the promising application for the ROS-sensitive drug release particles in dispelling the toxicity and suppressing the inflammation of PM2.5 pollutes, shedding a new light in the design and applications of stimuli-responsive systems in the bionanotechnology and healthcare fields.